我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

氯吡格雷低反应的危险因素及预后

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2014年第5期
页码:
583-587
栏目:
临床研究
出版日期:
2014-05-25

文章信息/Info

Title:
Analysis of risk factors and prognosis of low clopidogrel responsiveness
作者:
牟彦红; 彭 瑜; 丁丽琼; 胡雪婷; 潘晨亮; 韩 霞; 张 钲
(兰州大学第一医院心内科，甘肃 兰州 730000)
Author(s):
MU Yan-hong;  PENG Yu;  DING Li-qiong;  HU Xue-ting;  PAN Chen-liang;  HAN Xia;  ZHANG Zheng
(Department of Cardiology, First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China)
关键词:
冠状动脉疾病; 氯吡格雷低反应; 危险因素; 心血管事件
Keywords:
coronary disease;  low clopidogrel responsiveness;  risk factors;  recurrent cardiovascular events
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的:探讨冠心病患者氯吡格雷低反应的危险因素以及与支架植入术后心血管事件之间的关系。方法： 冠心病患者400例，均口服氯吡格雷常规剂量75 mg/d治疗3 d以上或顿服氯吡格雷负荷量300 mg 6 h以上。以10 μmol/L二磷酸腺苷(adenonisine disphosphate，ADP)为诱导剂，利用比浊法检测血小板聚集率，根据检测结果将患者分为氯吡格雷低反应和氯吡格雷正常反应两组，比较两组临床及生化指标的差异，运用Logistic回归分析进一步探讨氯吡格雷低反应的影响因素。并随访观察两组患者术后9个月的心血管事件，包括围术期心肌梗死、支架内血栓、急性心肌梗死、心因性死亡和卒中。结果： 氯吡格雷低反应的发生率为19.8%。氯吡格雷低反应组和氯吡格雷正常反应组血小板聚集率分别为（49±9）%和（18±11）%（P<0.01）。二元Logistic 回归分析显示糖尿病(OR 1.954,95%CI 1.036-3.683，P<0.05)、高脂血症(OR 1.915,95%CI 1.014-3.617，P<0.05)及血浆纤维蛋白原(OR 1.431,95%CI 1.089-1.882，P<0.05)是氯吡格雷低反应的危险因素。随访观察中氯吡格雷低反应组终点事件的发生率显著高于氯吡格雷正常反应组，差异具有统计学意义（20% vs. 12%,P<0.05）。结论： 糖尿病、高脂血症、血浆纤维蛋白原与既往PCI史是氯吡格雷低反应的影响因素。与氯吡格雷正常反应组相比，氯吡格雷低反应组终点事件的发生率显著增加。
Abstract:
AIM:To assess the risk factors of low clopidogrel responsiveness in patients with coronary heart disease (CHD) and analyze the relationship between low clopidogrel responsiveness and recurrent cardiovascular events after PCI. METHODS: A total of 400 patients with CHD were assigned to clopidogrel low responder group (n=79) and responder group (n=321) according to the results of ADP (10 μmol/L)-induced platelet aggregation. All patients received a conventional dose of clopidogrel for 3 days or more or oral 300 mg loading dose of clopidogrel for at least 6 h. Possible risk factors of low clopidogrel responsiveness were analyzed by single factor analysis and multifactor gradual logistic regression analysis. All patients were followed for 9 months after PCI and the primary endpoint was perioperative myocardial infarction, stent thrombosis, acute myocardial infarction, cardiac death and stroke. RESULTS: The incidence of low clopidogrel responsiveness was 19.8%. Platelet aggregation rates were (49±9) and (18±11), respectively, in the two groups (P<0.01). Multivariate logistic regression analysis found that low clopidogrel responsiveness was positively correlated with diabetes mellitus (OR 1.954, 95%CI 1.036-3.683, P<0.05), hyperlipidemia (OR 1.915, 95%CI 1.014-3.617, P<0.05) and plasma fibrinogen (OR 1.431, 95%CI 1.089-1.882, P<0.05). Cardiovascular events occurred in 16 patients (20%) in the low clopidogrel responsiveness group and 37 patients (12%) in the control group. CONCLUSION: Diabetes mellitus, hyperlipidemia, plasma fibrinogen and the history of prior PCI are the influencing factors of low clopidogrel responsiveness. Low clopidogrel responsiveness increases the incidence of recurrent cardiovascular events.

参考文献/References

[1]Wijns W,Kolh P,Danchin N,et al.Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS)[J].Eur Heart J,2010,31(20):2501-2555.
[2]Aradi D,Komócsi A,Vorobcsuk A,et al.Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis[J].Am Heart J,2010,160(3):543-551.
[3]Cuisset T,Cayla G,Silvain J.Clopidogrel resistance: what's new?[J].Arch Cardiovasc Dis,2010,103(6/7):349-353.
[4]Thygesen K,Alpert JS,Jaffe AS,et al.Third Universal definition of myocardial infarction[J].J Am Coll Cardiol,2012,33(20):2551-2567.
[5]Cutlip DE, Windecker S,Mehran R,et al.Clinical end points in coronary stent trials: a case for standardized definitions[J]. Circulation,2007,115(17):2344-2351.
[6]Angiolillo DJ,Fernandez-Ortiz A,Bernardo E,et al.Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting[J].Thromb Res, 2005, 115(1/2):101-108.
[7]Angiolillo DJ, Fernández-Ortiz A,Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?［J］. J Invasive Cardiol,2004,16(4):169-174.
[8]Tantry US,Jeong YH, Navarese EP,et al.Influence of genetic polymorphisms on platelet function,response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease[J].Expert Rev Cardiovasc Ther,2013,11(4):447-462.
[9]Kirtane AJ,Stone GW.How to minimize stent thrombosis[J].Circulation,2011,124(11):1283-1287.
[10]Buonamici P,Marcucci R,Migliorini A,et al.Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis[J].J Am Coll Cardiol,2007,49(24):2312-2317.
[11]杨 帆,赖沙毅,王 红.糖尿病患者经皮冠状动脉介入术后氯吡格雷抵抗的临床观察[J].心脏杂志 2010,22(3):390-392.
[12]Zimman A,Podrez EA.Regulation of platelet function by class B scavenger receptors in hyperlipidemia[J].Arterioscler Thromb Vasc Biol,2010,30(12):2350-2356.
[13]杨 帆,赖沙毅,王 红.经皮冠状动脉介入术后氯吡格雷抵抗的临床观察[J].柳州医学,2010,20(4):141-143.
[14]Gurbel PA,Samara WM,Bliden KP.Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis[J].Platelets,2004,15(2):95-99.
[15]Aradi D,Komócsi A,Vorobcsuk A,et al.Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis[J].Am Heart J,2010,160(3):543-551.

备注/Memo

备注/Memo:
收稿日期：2014-01-06.
通讯作者：张钲，主任医师，主要从事冠心病和心电生理与起搏临床和基础研究 Email：zhangccu@163.com
作者简介：牟彦红，硕士生 Email:mouyhong06@163.com
更新日期/Last Update: 2014-06-05